DHAVAL RAMESHCHANDRA SHAH MD NPI 1063743722

NPI Details

Dhaval Rameshchandra Shah, MD is a hematology and oncology internal medicine in Newark, DE with 20 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Dhaval Rameshchandra Shah, MD NPI is 1063743722. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4701 OGLETOWN STANTON RD
SUITE 3400
NEWARK, DE
ZIP 19713-055
Phone: (609) 702-1900
Fax: (302) 366-1700

The NPI 1063743722 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Collection of blood sample from implanted device (HCPCS:36591)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection of drug or substance into vein (HCPCS:96374)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Advance care planning, first 30 minutes (HCPCS:99497)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)

The enumeration date for this NPI number is 1/20/2010 and was last updated on 4/12/2016.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: